Company news

Biocogniv Closes $6M in Seed Funding Led By Breyer Capital to Advance Digital Diagnostic Platform

Company Adds Multiple Healthcare Industry Leaders to Advisory Board

March 16, 2022 (Burlington, VT) — Biocogniv, a digital diagnostic company focused on predicting time-critical medical conditions using artificial intelligence (AI) on top of laboratory data, today announced the closing of its $6M rolling seed round led by Breyer Capital, with participation from Y Combinator, 1984 Ventures, Inflect Health, Promus Ventures, The Fund at Hula, as well as several prominent angel investors, including Boston Scientific’s co-founder John Abele, IBM’s former CEO Sam Palmisano, LabCorp’s former EVP, CMO, and CSO Myla Lai-Goldman, MD, Paige.AI’s former CEO Leo Grady, PhD, and Syapse’s founder and former President Jonathan Hirsch. As part of this round of financing, Myla Lai-Goldman, Leo Grady, and Jonathan Hirsch will also be joining Biocogniv’s Advisory Board. 

“In hospital settings, every hour of delayed care can lead to long-term morbidity and, in some cases, death. With sepsis for example – the leading cause of in-hospital death in the US – delayed or inappropriate care has a mortality burden equivalent to that of prostate cancer, killing more than 30,000 Americans per year,” says Biocogniv’s CEO and former National Institutes of Health faculty member, Artur Adib, PhD. “At Biocogniv, we are propelling acute care into a future where most of these deaths are averted, leveraging state-of-the-art AI on top of laboratory data. The caliber of our new investors and advisors is a testament to the importance of this work.”

Using real-world laboratory data from hundreds of hospitals and strategic partners, Biocogniv has created aiMarkers™, predictive AI models that can detect acute conditions before they become irreversible, and clinOS™, a real-time, cloud-based platform that deploys those models into clinical care. The company will use the new funding to further develop and validate its aiMarkers™ and clinOS™ platform.

“aiMarkers™ are yet another example of the untapped potential of AI in healthcare. Biocogniv's nimble team has been tackling the hard problems involved in bringing this innovation to clinical practice, attracting key industry partners and thought leaders along the way. As long-term believers in the disruptive power of AI in healthcare, we couldn’t be more excited to join forces with them,” said venture capital pioneer Jim Breyer, founder and CEO of Breyer Capital.

“Many companies are building AI for patient care, often without the proper rigor and clinical validation required for broad adoption in medicine,” said Leo Grady, PhD, CEO-in-Residence at Breyer Capital, who spearheaded the first FDA approval for an AI product in pathology as CEO of Paige.AI. “I am impressed with the results and progress that Biocogniv was able to achieve in a short period of time and I look forward to helping the company in this next phase.”

About Breyer Capital

Breyer Capital is a premier global venture capital and private equity investor focused on catalyzing high-impact entrepreneurs in the US and China. Founded by legendary investor Jim Breyer in 2006, Breyer Capital makes long-term, idea-driven strategic investments in artificial intelligence, digital health, data analytics, social media, and financial technologies. The firm prides itself on maintaining an openness to experimentation that can lead to long-term breakthrough performance and partnering with founders and teams who are passionate about building transformative companies anchored in technology. For more information, please visit

About Biocogniv

Biocogniv is the world’s first digital diagnostic company tackling time-critical conditions using artificial intelligence on top of laboratory data. The company’s software platform, clinOS™, is already connected to multiple hospital systems across the US, processing thousands of laboratory tests per day, and its pipeline of aiMarkers™ includes predictors for sepsis, respiratory failure, acute heart failure, and others. For more information, please visit